Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and A disintegrin and metalloproteinases in hypertension and cardiac disease

Journal of Vascular Research

Volumn 50, Issue 1, 2012, Pages 52-68

  Berry, Evan ^a   Bosonea, Ana Maria ^a   Wang, Xiang ^a   Fernandez Patron, Carlos ^a,b  

^a School of Translational Medicine   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

A disintegrin and metalloproteinase; G protein coupled receptor; Hypertension; Hypertrophy; Lipids; Matrix metalloproteinase; Metalloproteinases

Indexed keywords

ADAM 12 PROTEIN; ADAM PROTEIN; AE 941; CARRIER PROTEIN; DOXYCYCLINE; GELATINASE A; LIPID; LIPOPROTEIN; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; PRINOMASTAT; TANOMASTAT; TETRACYCLINE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

AORTA ANEURYSM; BLOOD PRESSURE; BLOOD VESSEL WALL; CHEMICAL MODIFICATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME REGULATION; HEART DISEASE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; INTRACRANIAL ANEURYSM; MARFAN SYNDROME; MUSCULOSKELETAL PAIN; NEOPLASM; NONHUMAN; PERIODONTITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

ADAM PROTEINS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART DISEASES; HUMANS; HYPERTENSION; LIPID METABOLISM; LIPOPROTEINS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84869215612     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000345240     Document Type: Review

References (197)

1. Jones DW, Hall JE: World Hypertension Day 2007. Hypertension 2007; 49:939-940. (Pubitemid 351664339)
2. Biaggioni I: Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension 2008; 51: 168-171. (Pubitemid 351159921)
3. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA: The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302:H1219-1230.
4. Fernandez-Patron C: Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxi-dative stress, and hypertrophic growth downstream of vasoactive G-protein-cou-pled receptors? Can J Physiol Pharmacol 2007; 85:97-104. (Pubitemid 46996108)
5. Lifton RP, Gharavi AG, Geller DS: Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556. (Pubitemid 32201949)
6. Strongin AY: Proteolytic and non-proteolyt-ic roles of membrane type-1 matrix metal-loproteinase in malignancy. Biochim Bio-phys Acta 2010; 1803: 133-141.
7. Turner AJ, Hooper NM: Role for ADAM-family proteinases as membrane protein secretases. Biochem Soc Trans 1999; 27:255-259. (Pubitemid 29086044)
8. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A: The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol 2012; 91:472-485.
9. Shiomi T, Lemaitre V, D'Armiento J, Okada Y: Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospon-din motifs in non-neoplastic diseases. Pathol Int 2010; 60:477-496.
10. Raffetto JD, Khalil RA: Matrix metallopro-teinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359. (Pubitemid 350298459)
11. Korpos E, Wu C, Sorokin L: Multiple roles of the extracellular matrix in inflammation. Curr Pharm Des 2009; 15:1349-1357.
12. Gooz P, Gooz M, Baldys A, Hoffman S: ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angio-genesis. Biochem Biophys Res Commun 2009; 380:33-38.
13. Johnson JL: Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardio-vasc Ther 2007; 5:265-282. (Pubitemid 46488141)
14. Thompson M, Cockerill G: Matrix metallo-proteinase-2: the forgotten enzyme in aneu-rysm pathogenesis. Ann NY Acad Sci 2006; 1085:170-174. (Pubitemid 47092005)
15. Lijnen HR: Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003; 33: 275-281. (Pubitemid 40278695)
16. Zile MR, Baicu CF, Stroud RE, Van Laer AO, Arroyo J, Mukherjee R, Jones JA, Spinale FG: Pressure-overload dependent membranetype 1 matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol 2012; 302:H1429-1437.
17. Spinale FG: Diversity of myocardial interstitial proteolytic pathways: gene deletion reveals unexpected consequences. Circulation 2011; 124:2052-2055.
18. Sahul ZH, Mukherjee R, Song J, McAteer J, Stroud RE, Dione DP, Staib L, Papademetris X, Dobrucki LW, Duncan JS, Spinale FG, Si-nusas AJ: Targeted imaging of the spatial and temporal variation of matrix metallopro-teinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging 2011; 4:381-391.
19. Spinale FG, Wilbur NM: Matrix metallopro-teinase therapy in heart failure. Curr Treat Options Cardiovasc Med 2009; 11:339-346.
20. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C: MMP-2 mediates angiotensin II-induced hypertension under the transcrip-tional control of MMP-7 and TACE. Hypertension 2011; 57: 123-130.
21. Wang X, Oka T, Chow FL, Cooper SB, Oden-bach J, Lopaschuk GD, Kassiri Z, Fernandez-Patron C: Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hyper tension 2009; 54: 575-582.
22. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan BA, Schulz R, Kassiri Z, Lo-paschuk GD, Fernandez-Patron C: Matrix metalloproteinase-7 and ADAM-12 (a disin-tegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009; 119: 2480-2489.
23. Nagareddy PR, Chow FL, Hao L, Wang X, Nishimura T, MacLeod KM, McNeill JH, Fernandez-Patron C: Maintenance of adren-ergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochon-drial ATP synthesis. Cardiovasc Res 2009; 84:368-377.
24. Hao L, Nishimura T, Wo H, Fernandez-Patron C: Vascular responses to alpha1-adren-ergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Ar ter ioscler T hromb Vasc Biol 2006; 26: 819-825. (Pubitemid 43732157)
25. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C: Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004; 94: 68-76. (Pubitemid 38064100)
26. Zhang MG: Transcriptional Regulatory Element Database. Cold Spring Harbor Laboratory. http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home.
27. Browatzki M, Larsen D, Pfeiffer CA, Gehrke SG, Schmidt J, Kranzhofer A, Katus HA, Kranzhofer R: Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear fac-tor-kappaB and activator protein 1 in a re-dox-sensitive manner. J Vasc Res 2005; 42: 415-423. (Pubitemid 41368960)
28. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884-888.
29. Eferl R, Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868. (Pubitemid 37383716)
30. Li X, Stark GR: NFkappaB-dependent signaling pathways. Exp Hematol 2002; 30:285-296.
31. Overall CM, Lopez-Otin C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657-672. (Pubitemid 37328917)
32. Wu KI, Schmid-Schonbein GW: Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat. Hypertension 2011; 57: 261-268.
33. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM: Inflammation, immunity, and hypertension. Hy per tension 2011; 57: 132-140.
34. Fedak PW, Moravec CS, McCarthy PM, Al-tamentova SM, Wong AP, Skrtic M, Verma S, Weisel RD, Li RK: Altered expression of dis-integrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006; 113: 238-245.
35. Van Wart HE, Birkedal-Hansen H: The cys-teine switch: a principle of regulation of me-talloproteinase activity with potential applicability to the entire matrix metalloprotein-ase gene family. Proc Natl Acad Sci USA 1990; 87:5578-5582.
36. Cauwe B, Opdenakker G: Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010; 45: 351-423.
37. Edwards DR, Handsley MM, Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med 2008; 29: 258-289.
38. Murphy G, Willenbrock F, Crabbe T, O'Shea M, Ward R, Atkinson S, O'Connell J, Do-cherty A: Regulation of matrix metallopro-teinase activity. Ann NY Acad Sci 1994; 732: 31-41.
39. Zhao Y, Lyons CE Jr, Xiao A, Templeton DJ, Sang QA, Brew K, Hussaini IM: Urokinase directly activates matrix metalloproteinas-es-9: a potential role in glioblastoma invasion. Biochem Biophys Res Commun 2008; 369:1215-1220.
40. Schulz R: Intracellular targets of matrix me-talloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Tox icol 2007; 47: 211-242.
41. Turrens JF: Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552: 335-344. (Pubitemid 37321833)
42. Chase AJ, Newby AC: Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J Vasc Res 2003; 40:329-343. (Pubitemid 37188102)
43. Murphy G: Tissue inhibitors of metallopro-teinases. Genome Biol 2011; 12: 233.
44. Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD, Overall CM: Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem 2001; 276:47402-47410.
45. Frears ER, Zhang Z, Blake DR, O'Connell JP, Winyard PG: Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 1996; 381:21-24. (Pubitemid 26070416)
46. Brown DJ, Lin B, Chwa M, Atilano SR, Kim DW, Kenney MC: Elements of the nitric oxide pathway can degrade TIMP-1 and increase gelatinase activity. Mol Vis 2004; 10: 281-288. (Pubitemid 38628950)
47. 2+ exchanger by peroxynitrite in microsomes of pulmonary smooth muscle: role of matrix metallopro-teinase-2. Biochim Biophys Acta 2004; 1671: 70-78. (Pubitemid 38327131)
48. Donnini S, Monti M, Roncone R, Morbidelli L, Rocchigiani M, Oliviero S, Casella L, Gia-chetti A, Schulz R, Ziche M: Peroxynitrite inactivates human-tissue inhibitor of metal-loproteinase-4. FEBS Lett 2008; 582:1135-1140.
49. Brinckerhoff CE, Matrisian LM: Matrix me-talloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3:207-214.
50. Kumari S, Mg S, Mayor S: Endocytosis unplugged: multiple ways to enter the cell. Cell Res 2010; 20:256-275.
51. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23. (Pubitemid 28317502)
52. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2-de-pendent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000; 87:670-676.
53. Fernandez-Patron C, Radomski MW, Da-vidge ST: Vascular matrix metalloprotein-ase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85: 906-911. (Pubitemid 29534165)
54. Kohan DE, Rossi NF, Inscho EW, Pollock DM: Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011; 91:1-77.
55. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cut-titta F: Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004; 383: 413-418. (Pubitemid 39546110)
56. Schafer B, Marg B, Gschwind A, Ullrich A: Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 2004; 279: 47929-47938. (Pubitemid 39540944)
57. Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE: Transactivation of epidermal growth factor receptor mediates catechol-amine-induced growth of vascular smooth muscle. Circ Res 2004; 95:989-997. (Pubitemid 39532329)
58. Merklinger SL, Jones PL, Martinez EC, Rabi-novitch M: Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005; 112: 423-431. (Pubitemid 41022085)
59. Chen J, Chen JK, Neilson EG, Harris RC: Role of EGF receptor activation in angioten-sin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol 2006; 17:1615-1623. (Pubitemid 43794664)
60. Cauwe B, Van den Steen PE, Opdenakker G: The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007; 42: 113-185. (Pubitemid 46911962)
61. Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schonbein GW: Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010; 299:H25-35.
62. Chen AY, DeLano FA, Valdez SR, Ha JN, Shin HY, Schmid-Schonbein GW: Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat. Am J Physiol Cell Physiol 2010; 299:C1441-1449.
63. Tran ED, DeLano FA, Schmid-Schonbein GW: Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J Vasc Res 2010; 47: 423-431.
64. DeLano FA, Schmid-Schonbein GW: Pro-teinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension 2008; 52:415-423.
65. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-1549.
66. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P, Schulz R: Matrix metalloproteinase-2 mediates cy-tokine-induced myocardial contractile dys-f unction. Cardiovasc Res 2003; 57: 426-433. (Pubitemid 36144221)
67. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R: Degradation of myosin light chain in isolated rat hearts subjected to isch-emia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005; 112:544-552. (Pubitemid 41060795)
68. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R: Matrix metal-loproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007; 43:429-436. (Pubitemid 47451426)
69. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R: Titin is a target of matrix metalloproteinase-2: implications in myo-cardial ischemia/reperfusion injury. Circulation 2010; 122:2039-2047.
70. Snoek-van Beurden PA, Von den Hoff JW: Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005; 38:73-83. (Pubitemid 40139420)
71. Stack MS, Gray RD: Comparison of vertebrate collagenase and gelatinase using a new fluorogenic substrate peptide. J Biol Chem 1989; 264:4277-4281. (Pubitemid 19081323)
72. Yan SJ, Blomme EA: In situ zymography: a molecular pathology technique to localize endogenous protease activity in tissue sections. Vet Pathol 2003; 40:227-236. (Pubitemid 38393570)
73. Doucet A, Overall CM: Protease proteomics: revealing protease in vivo functions using systems biology approaches. Mol Aspects Med 2008; 29:339-358.
74. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY: Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004; 101:17867-17872. (Pubitemid 40051978)
75. Schiffrin EL: Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004; 17:1192-1200. (Pubitemid 40029420)
76. Schmid-Schönbein GW: An emerging role of degrading proteinases in hypertension and the metabolic syndrome: autodigestion and receptor cleavage. Curr Hypertens Rep 2011; 14: 88-96.
77. Martinez-Lemus LA: Persistent agonist-induced vasoconstriction is not required for angiotensin II to mediate inward remodeling of isolated arterioles with myogenic tone. J Vasc Res 2008; 45: 211-221. (Pubitemid 351543145)
78. Martinez-Lemus LA, Zhao G, Galinanes EL, Boone M: Inward remodeling of resistance arteries requires reactive oxygen species-dependent activation of matrix metallopro-teinases. Am J Physiol Heart Circ Physiol 2011; 300:H2005-2015.
79. Hill MA, Potocnik SJ, Martinez-Lemus LA, Meininger GA: Delayed arteriolar relaxation after prolonged agonist exposure: functional remodeling involving tyrosine phosphoryla-tion. Am J Physiol Heart Circ Physiol 2003; 285:H849-856.
80. Martinez-Lemus LA, Galinanes EL: Matrix metalloproteinases and small artery remodeling. Drug Discov Today Dis Models 2011; 8: 21-28.
81. Martinez-Lemus LA, Hill MA, Bolz SS, Pohl U, Meininger GA: Acute mechanoadapta-tion of vascular smooth muscle cells in response to continuous arteriolar vasoconstriction: implications for functional remodeling. FASEB J 2004; 18: 708-710.
82. Lemarie CA, Tharaux PL, Lehoux S: Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol 2010; 48:433-439.
83. Belz GG: Elastic properties and Windkessel function of the human aorta. Cardiovasc Drugs Ther 1995; 9: 73-83.
84. McNulty M, Mahmud A, Spiers P, Feely J: Collagen type-I degradation is related to arterial stiffness in hypertensive and normo-tensive subjects. J Hum Hypertens 2006; 20: 867-873. (Pubitemid 44614069)
85. Chung AW, Yang HH, Kim JM, Sigrist MK, Chum E, Gourlay WA, Levin A: Upregula-tion of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009; 120: 792-801.
86. Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA: Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 2004; 24:1479-1484. (Pubitemid 39050444)
87. Yasmin, McEniery CM, O'Shaughnessy KM, Harnett P, Arshad A, Wallace S, Maki-Petaja K, McDonnell B, Ashby MJ, Brown J, Cock-croft JR, Wilkinson IB: Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006; 26: 1799-1805. (Pubitemid 44305333)
88. Lim H, Zhu YZ: Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 2006; 63: 2584-2596. (Pubitemid 44800713)
89. Van Lint P, Libert C: Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007; 82:1375-1381. (Pubitemid 350276947)
90. Imai K, Hira matsu A, Fukushima D, Piersch-bacher MD, Okada Y: Degradation of deco-rin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997; 322:809-814. (Pubitemid 27135628)
91. Morgunova E, Tuuttila A, Bergmann U, Isu-pov M, Lindqvist Y, Schneider G, Tryggva-son K: Structure of human pro-matrix me-talloproteinase-2: activation mechanism revealed. Science 1999; 284:1667-1670. (Pubitemid 29291376)
92. Flamant M, Placier S, Dubroca C, Esposi-to B, Lopes I, Chat zia ntoniou C, Tedgui A, Dussaule JC, Lehoux S: Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007; 50: 212-218. (Pubitemid 46986043)
93. Lehoux S, Lemarie CA, Esposito B, Lijnen HR, Tedgui A: Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 2004; 109:1041-1047. (Pubitemid 38282859)
94. Kurisaki T, Masuda A, Sudo K, Sakagami J, Higashiyama S, Matsuda Y, Nagabukuro A, Tsuji A, Nabeshima Y, Asano M, Iwakura Y, Sehara-Fujisawa A: Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: involvement of Meltrin alpha in adipogen-esis and myogenesis. Mol Cell Biol 2003; 23: 55-61. (Pubitemid 36008500)
95. Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM: Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol 2008; 40: 1685-1702.
96. Liao Y, Zhao H, Ogai A, Kato H, Asakura M, Kim J, Asanuma H, Minamino T, Ta-kashima S, Kitakaze M: Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 2008; 31:335-344. (Pubitemid 351461114)
97. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S: Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8: 35-40. (Pubitemid 34101726)
98. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM: ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278: 511-515.
99. Kang Q, Cao Y, Zolkiewska A: Metallopro-tease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyro-sine kinase in C2C12 cells. Biochem J 2000; 352: 883-892. (Pubitemid 32015046)
100. Kang Q, Cao Y, Zolkiewska A: Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells. J Biol Chem 2001; 276: 24466-24472.
101. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloprotein-ase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729-733. (Pubitemid 27098094)
102. Gooz M: ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010; 45: 146-169.
103. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA: An essential role for ectodomain shedding in mammalian development. Science 1998; 282:1281-1284. (Pubitemid 28524483)
104. Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, Lauro D, Sbraccia P, Hribal ML, Lauro R, Federici M: Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007; 56: 2541-2546. (Pubitemid 47523261)
105. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S: ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 2006; 26:e133-137.
106. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S: G protein coupling and second messenger generation are indispensable for metalloprotease-depen-dent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 2005; 280: 26592-26599. (Pubitemid 41022257)
107. Kruger A, Kates RE, Edwards DR: Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 2010; 1803:95-102.
108. Overall CM, Kleifeld O: Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6:227-239. (Pubitemid 43292566)
109. Zile MR, Desantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, Mehurg SM, Spinale FG: Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011; 4: 246-256.
110. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY: Tissue inhibitor of metalloprotein-ase-1 and matrix metalloproteinase-9 levels in patients with hypertension: relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004; 17:770-774. (Pubitemid 39201091)
111. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB: Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 372.
112. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J: Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-540. (Pubitemid 28371251)
113. Saglam M, Karakaya O, Esen AM, Barutcu I, Dogan S, Karavelioglu Y, Karapinar H, Akgun T, Esen O, Ozdemir N, Turkmen S, Kaymaz C: Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dys-f u nc t ion in hy per tensi ve su bject s. Tohok u J Exp Med 2006; 208:117-122. (Pubitemid 43174163)
114. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY: Matrix metallopro-teinase-9 and tissue inhibitor metallopro-teinase-1 levels in essential hypertension: relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75: 43-47.
115. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, Mc-Clure CD, Spinale FG, Zile MR: Matrix me-talloproteinases/tissue inhibitors of metal-loproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096.
116. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C, Vasiliadou K, Toutouza M, Toutouzas P: Plasma levels of active extracellular matrix metallopro-teinases 2 and 9 in patients with essential hypertension before and after antihyper-tensive treatment. J Hum Hypertens 2003; 17:119-124. (Pubitemid 36292367)
117. Derosa G, D'Angelo A, Ciccarelli L, Piccin-ni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Ti-nelli C, Cicero AF: Matrix metalloprotein-ase-2,-9, and tissue inhibitor of metallopro-teinase-1 in patients with hypertension. En-dot helium 2006; 13: 227-231. (Pubitemid 44110588)
118. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K: Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115:888-895. (Pubitemid 46294729)
119. Onal IK, Altun B, Onal ED, Kirkpantur A, Gul Oz S, Turgan C: Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med 2009; 20:369-372.
120. 2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and-9 in essential hypertension. Am J Hyper tens 2004; 17: 273-276. (Pubitemid 38293334)
121. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J: Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48:89-96.
122. Stakos DA, Tziakas DN, Chalikias GK, Mi-trousi K, Tsigalou C, Boudoulas H: Associations between collagen synthesis and degradation and aortic function in arterial hy pertension. Am J Hyper tens 2010; 23: 488-494.
123. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hy pertens 2004; 17: 764-769. (Pubitemid 39201090)
124. Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z: Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007; 30:959-963. (Pubitemid 350120974)
125. Friese RS, Rao F, Khandrika S, Thomas B, Ziegler MG, Schmid-Schonbein GW, O'Connor DT: Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens 2009; 31:521-533.
126. Hirono O, Fatema K, Nitobe J, Takeishi Y, Ka neko K, Sh iga R, Kubot a I: Long-ter m effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension. J Cardiol 2002; 39: 195-204. (Pubitemid 40756057)
127. Szmigielski C, Raczkowska M, Styczynski G, Pruszczyk P, Gaciong Z: Metabolism of collagen is altered in hypertensives with increased intima media thickness. Blood Press 2006; 15:157-163. (Pubitemid 44644467)
128. Gonzalez A, Lopez B, Querejeta R, Zubilla-ga E, Echeverria T, Diez J: Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010; 55:1418-1424.
129. Franz M, Berndt A, Altendorf-Hofmann A, Fiedler N, Richter P, Schumm J, Fritzen-wanger M, Figulla HR, Brehm BR: Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009; 11:1057-1062.
130. Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM: Can emerging bio-markers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011; 13: 1087-1095.
131. Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, Guasti L, Ven-co A, Schiffrin EL, Lip GY, Grandi AM: Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hyper-tens 2012; 30:3-16.
132. Fielitz J, Leuschner M, Zurbrugg HR, Han-nack B, Pregla R, Hetzer R, Regitz-Zagrosek V: Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med (Berl) 2004; 82: 809-820.
133. Rodriguez D, Morrison CJ, Overall CM: Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and pro-teomics. Biochim Biophys Acta 2010; 1803: 39-54.
134. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-2392. (Pubitemid 34270240)
135. Foronjy RF, Sun J, Lemaitre V, D'Armiento J M: Transgenic expression of matrix metal-loproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model. Hy-pertens Res 2008; 31: 725-735. (Pubitemid 351772864)
136. Fisher JF, Mobashery S: Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006; 25:115-136. (Pubitemid 43723987)
137. Peterson JT: Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9: 63-79. (Pubitemid 38202142)
138. Nelson ML, Levy SB: The history of the tet-racyclines. Ann NY Acad Sci 2011; 1241:17-32.
139. Chung AW, Yang HH, Radomski MW, van Breemen C: Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metallopro-teinase-2 and-9. Circ Res 2008; 102:e73-85.
140. Makino H, Tada Y, Wada K, Liang EI, Chang M, Mobashery S, Kanematsu Y, Kurihara C, Palova E, Kanematsu M, Kitazato K, Hashimoto T: Pharmacological stabilization of in-tracranial aneurysms in mice: a feasibility study. Stroke 2012; 43:2450-2456.
141. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE: Metalloprotein-ase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-331. (Pubitemid 351707391)
142. Nagareddy PR, Rajput PS, Vasudevan H, McClure B, Kumar U, Macleod KM, McNeill JH: Inhibition of matrix metallopro-teinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats. Br J Pharmacol 2012; 165:705-715.
143. Pires PW, Rogers CT, McClain JL, Garver HS, Fink GD, Dorrance AM: Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2011; 301:H87-97.
144. Zeng S, Zhou X, Tu Y, Yao M, Han ZQ, Gao F, Li YM: Long-term MMP inhibition by doxycycline exerts divergent effect on ventricular extracellular matrix deposition and systolic performance in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 2011; 33:316-324.
145. Vinet L, Rouet-Benzineb P, Marniquet X, Pellegrin N, Mangin L, Louedec L, Samuel JL, Mercadier JJ: Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction. Am J Physiol Heart Circ Physiol 2008; 295:H352-360.
146. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P: Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hyper tension 2005; 45: 432-437. (Pubitemid 40315814)
147. Sloan B, Scheinfeld N: The use and safety of doxycycline hyclate and other second-generation tet racycli nes. E xper t Opin Dr ug Saf 2008; 7:571-577.
148. Cowley AW Jr, Nadeau JH, Baccarelli A, Be-recek K, Fornage M, Gibbons GH, Harrison DG, Liang M, Nathanielsz PW, O'Connor DT, Ordovas J, Peng W, Soares MB, Szyf M, Tolunay HE, Wood KC, Zhao K, Galis ZS: Report of the National Heart, Lung, and Blood Institute Working Group on epi-genetics and hypertension. Hypertension 2012; 59: 899-905.
149. Vinolo MA, Hirabara SM, Curi R: G-pro-tein-coupled receptors as fat sensors. Curr Opin Clin Nutr Metab Care 2012; 15:112-116.
150. Stolar M: Metabolic syndrome: controversial but useful. Cleve Clin J Med 2007; 74: 199-202, 205-208.
151. Nisoli E, Clementi E, Carruba MO, Monca-da S: Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 2007; 100:795-806. (Pubitemid 46555684)
152. Fisler JS, Warden CH: Uncoupling proteins, dietary fat and the metabolic syndrome. Nutr Metab (Lond) 2006; 3:38.
153. Savage DB, Petersen KF, Shulman GI: Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45:828-833. (Pubitemid 40628921)
154. Marx J: Medicine. Low-power mitochondria may raise risk of cardiovascular problems. Science 2005; 307: 334-335.
155. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, Sharaf BL, Pepine CJ, Sopko G, Reis SE: Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109: 714-721. (Pubitemid 38222889)
156. Ricke WA, Smith GW, Smith MF: Matrix metalloproteinase expression and activity following prostaglandin F(2 alpha)-induced luteolysis. Biol Reprod 2002; 66:685-691. (Pubitemid 34193925)
157. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8:289-293. (Pubitemid 34250108)
158. Porter KE, Turner NA: Statins and myocar-dial remodelling: cell and molecular pathways. Exper t Rev Mol Med 2011; 13:e22.
159. Kota B, Huang T, Roufogalis B: An overview on biological mechanisms of PPARs. Pharmacol Res 2005; 51: 85-94. (Pubitemid 40040538)
160. Wahli W, Braissant O, Desvergne B: Peroxi-some proliferator activated receptors: tran-scriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 1995; 2: 261-266.
161. Barger PM, Kelly DP: PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 2000; 10:238-245. (Pubitemid 32229879)
162. Kim JK, Mun S, Kim M-S, Kim M-B, Sa B-K Hwang J-K: 5, 7-Dimethoxyflavone, an activator of PPARa/7, inhibits UVB-induced MMP expression in human skin fibroblast cells. Exp Dermatol 2012; 21:211-216.
163. Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW, Wright SD, Cai TQ: Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not inter-leukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000; 267: 345-349. (Pubitemid 30072554)
164. Barger PM, Brandt JM, Leone TC, Wein-heimer CJ, Kelly DP: Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000; 105:1723-1730. (Pubitemid 30421753)
165. Teres S, Barcelo-Coblijn G, Benet M, Alvarez R, Bressani R, Halver JE, Escriba PV: Oleic acid content is responsible for the reduction in blood pressure induced by olive oil. Proc Natl Acad Sci USA 2008; 105: 13811-13816.
166. Berton A, Rigot V, Huet E, Decarme M, Eeckhout Y, Patthy L, Godeau G, Horne-beck W, Bellon G, Emonard H: Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids. J Biol Chem 2001; 276:20458-20465.
167. Puyraimond A, Fridman R, Lemesle M, Ar-beille B, Menashi S: MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res 2001; 262: 28-36. (Pubitemid 32989005)
168. Galvez BG, Matias-Roman S, Yanez-Mo M, Vicente-Manzanares M, Sanchez-Madrid F, Arroyo AG: Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol Biol Cell 2004; 15:678-687. (Pubitemid 38146484)
169. Ushio-Fukai M: Localizing NADPH oxi-dase-derived ROS. Sci STKE 2006; 2006:re8.
170. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK: LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008; 88: 887-918.
171. Emonard H, Bellon G, de Diesbach P, Mett-len M, Hornebeck W, Courtoy PJ: Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP): a new function for an 'old friend'. Biochimie 2005; 87: 369-376. (Pubitemid 40387616)
172. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK: The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989; 341: 162-164. (Pubitemid 19222781)
173. Van den Steen PE, Van Aelst I, Hvidberg V, Piccard H, Fiten P, Jacobsen C, Moes-trup SK, Fry S, Royle L, Wormald MR, Wallis R, Rudd PM, Dwek RA, Opdena-kker G: The hemopexin and O-glycosylat-ed domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem 2006; 281: 18626-18637. (Pubitemid 44035522)
174. Moestrup SK, Verroust PJ: Megalin-and cubilin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia. Annu Rev Nutr 2001; 21:407-428. (Pubitemid 32695278)
175. Moestrup SK, Gliemann J, Pallesen G: Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992; 269: 375-382.
176. 2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1, 2 and PI3-kinase/Akt pathways. Car-diovasc Res 2007; 75: 118-128. (Pubitemid 46873511)
177. Selvais C, DAuria L, Tyteca D, Perrot G, Lemoine P, Troeberg L, Dedieu S, Noel A, Nagase H, Henriet P, Courtoy PJ, Marbaix E, Emonard H: Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J 2011; 25:2770-2781.
178. Liu Q, Zhang J, Tran H, Verbeek MM, Reiss K, Estus S, Bu G: LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Mol Neurodegener 2009; 4:17.
179. Rozanov DV, Hahn-Dantona E, Strickland DK, Strongin AY: The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem 2004; 279: 4260-4268. (Pubitemid 38199013)
180. Jung HO, Uhm JS, Seo SM, Kim JH, Youn H-J, Baek SH, Chung WS, Seung KB: Angiotensin II-induced smooth muscle cell migration is mediated by LDL receptor-related protein 1 via regulation of matrix metalloproteinase 2 expression. Biochem Biophys Res Commun 2010; 402: 577-582.
181. Song H, Li Y, Lee J, Schwartz AL, Bu G: Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 2009; 69:879-886.
182. Mantuano E, Inoue G, Li X, Takahashi K, Gaultier A, Gonias SL, Campana WM: The hemopexin domain of matrix metallopro-teinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein. J Neurosci 2008; 28: 11571-11582.
183. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006; 281:2120-2127. (Pubitemid 43845801)
184. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS: Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 1990; 265: 17401-17404.
185. Kristensen T, Moestrup SK, Gliemann J, Bendtsen L, Sand O, Sottrup-Jensen L: Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor. FEBS Lett 1990; 276:151-155.
186. Rajamanickam C, Sakthivel S, Kurian Joseph P, Athimoolam Janarthanan R: A novel serum protein of molecular weight 182 kDa: a molecular marker for an early detect ion of increased left ventricular mass in patients with cardiac hypertrophy. J Cardio-vasc Risk 1998; 5:335-338. (Pubitemid 29046518)
187. Rajamanickam C, Sakthivel S, Babu GJ, Lottspeich F, Kadenbach B: Cardiac isoform of alpha-2 macroglobin, a novel serum protein, may induce cardiac hypertrophy in rats. Basic Res Cardiol 2001; 96: 23-33.
188. Hackeng CM, Relou IA, Pladet MW, Gorter G, van Rijn HJ, Akkerman JW: Early platelet activation by low density lipoprotein via p38MAP kinase. Thromb Haemost 1999; 82: 1749-1756.
189. Lee JM, Choudhury RP: Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging t herapeutic targets. Heart 2007; 93: 559-564. (Pubitemid 46707106)
190. Robbesyn F, Auge N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, Salvayre R: High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal (corrected) growth factor receptor activation and subsequent matrix metallo-proteinase-2 upregulation. Arterioscler Thromb Vasc Biol 2005; 25:1206-1212. (Pubitemid 40776610)
191. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH: Plasma lipoproteins: apo-lipoprotein structure and function. J Lipid Res 1984; 25:1277-1294. (Pubitemid 15150638)
192. Park JY, Park JH, Jang W, Hwang IK, Kim IJ, Kim HJ, Cho KH, Lee ST: Apolipopro-tein A-IV is a novel substrate for matrix me-talloproteinases. J Biochem 2011; 151: 291-298.
193. Kim SY, Park SM, Lee S-T: Apolipoprotein C-II is a novel substrate for matrix metal-loproteinases. Biochem Biophys Res Commun 2006; 339:47-54. (Pubitemid 41697512)
194. Park JH, Park SM, Park KH, Cho KH, Lee ST: Analysis of apolipoprotein A-I as a substrate for matrix metalloproteinase-14. Bio-chem Biophys Res Commun 2011; 409: 58-63.
195. Park JH, Park S-M, Park S-H, Cho K-H, Lee S-T: Cleavage and functional loss of human apolipoprotein E by digestion of matrix me-talloproteinase-14. Proteomics 2008; 8: 2926-2935.
196. Aoki T, Sato D, Li Y, Takino T, Miyamori H, Sato H: Cleavage of apolipoprotein E by membrane-type matrix metalloprotein-ase-1 abrogates suppression of cell proliferation. J Biochem 2005; 137:95-99.
197. Marcel YL, Kiss RS: Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations. Curr Opin Lipidol 2003; 14:151-157. (Pubitemid 36521185)